Sale Of Sandoz: Will They Or Won't They? [Seeking Alpha]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Seeking Alpha
Sale Of Sandoz: Will They Or Won't They? Rumors and announcements have left Novartis (NYSE: NVS Richard Francis, CEO of Sandoz, will be resigning. Now, having Sandoz operate as an automated entity certainly could be interpreted as a move towards the ultimate divestiture of it, but then again, when the Chairman states the exact opposite, it makes investors wonder why the company has made this move in the first place. Overview of Sandoz Sandoz is the generic and biosimilar medicines division within Novartis. They are currently number 1 globally in biosimilars and generic antibiotics, dermatology, and transplantation medicines. They are also known for having received approval for the first-ever generic biotech drug way back in 2006. Sandoz's Historical Advantage Pharmaceutical companies have always struggled with patent cliff issues. Patent cliff issues arise when billions of dollars in revenue are linked to a small number of drugs that are reaching the end of their respective patents. A
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings [Yahoo! Finance]Yahoo! Finance
- Global Skeletal Dysplasia Market Projected to Reach USD 3.92 Billion by 2028, Growing at a CAGR of 7.09% [Yahoo! Finance]Yahoo! Finance
- Amgen (AMGN) Ascends While Market Falls: Some Facts to Note [Yahoo! Finance]Yahoo! Finance
- ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study [Yahoo! Finance]Yahoo! Finance
- Is Amgen Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- AMGN's page on the SEC website